The Department of Pathology at Yale School of Medicine engages in cutting-edge research in addition to supporting its robust clinical and teaching missions. Researchers in the Department of Pathology are conducting sponsored research into the underlying causes of disease as well as translational, pre-clinical and clinical studies to improve diagnostic methods and treatment options for patients. Below is a list of new major governmental, foundational and pharmaceutical research grants obtained by faculty in the department (start dates 8/1/2015 – 6/1/2016.)
Sam Katz, MD, PhD, has received money from Gabrielle’s Angel Foundation and the National heart, Lung and Blood Institute to study the roles and regulation of cell death in development and cancer.
Michael Krauthammer, MD, PhD, received funds from the National Cancer Institute to perform bioinformatics studies investigating viral transformation in cancer.
Katerina Politi, PhD, is the recipient of funding from the Yale Cancer Center to study naturally- occurring immune system interactions with cancer cells.
Kurt Schalper, MD, PhD, has received funding from the Lung Cancer SPORE to study immune cell interactions with tumors. In addition, he has funding from Vasculox and Tesaro, Inc., to elucidate the roles of several tumor markers.
Narendra Wajapeyee, PhD, has received three grants from the National Cancer Institute to characterize metabolic drivers and mechanisms of metastases in lung cancer and melanoma, and money from the American Cancer Society to study changes in the metabolism of melanoma cells.
Qin Yan, PhD, will use funding from the Skin SPORE to study the function of DNA remodeling in melanoma.
Kurt Schalper, MD, PhD, has received financial support from the Lung Cancer Research Foundation and Stand up to Cancer to develop novel quantitative diagnostic tumor assays to accurately predict response or resistance to new PD-1 inhibitor immunotherapies in lung cancer.
David Rimm, MD, PhD, is the recipient of grants from Therapies in Breast Cancer, Genoptix, the National Comprehensive Cancer Network and Stand up to Cancer, to improve breast and lung cancer diagnostics.
Sam Katz, MD, PhD, has received funding from two agencies, The National Cancer Institute and the Alliance for Gene Therapy, to improve the use of Chimeric Antigen Receptors, an exciting new area of cancer therapy aimed at the targeted destruction of tumor cells using modified immune cells.
Don Nguyen, PhD, received support from the Lung SPORE to study extracellular matrix targets in chemotherapy.
Katerina Politi, PhD, has received National Cancer Institute funding to determine mechanisms of drug resistance in specific forms of lung cancer.
John Rose, PhD, has received support from NIH to develop vaccines against dengue virus as well as to continue his work on therapeutic vaccines for treatment of hepatitis B.
Narendra Wajapeyee, PhD, has received funding from L2 Diagnostics to develop small molecule inhibitors of tumor cell growth.
David Rimm, MD, PhD, received funds from France’s Fondation Pierre Fabre to study insulin responsive aspects of immune-therapy for cancer.